These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21913181)

  • 1. Earlier age of onset of BRCA mutation-related cancers in subsequent generations.
    Litton JK; Ready K; Chen H; Gutierrez-Barrera A; Etzel CJ; Meric-Bernstam F; Gonzalez-Angulo AM; Le-Petross H; Lu K; Hortobagyi GN; Arun BK
    Cancer; 2012 Jan; 118(2):321-5. PubMed ID: 21913181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proven non-carriers in BRCA families have an earlier age of onset of breast cancer.
    Vos JR; de Bock GH; Teixeira N; van der Kolk DM; Jansen L; Mourits MJ; Oosterwijk JC
    Eur J Cancer; 2013 Jun; 49(9):2101-6. PubMed ID: 23490645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations.
    Lee JS; John EM; McGuire V; Felberg A; Ostrow KL; DiCioccio RA; Li FP; Miron A; West DW; Whittemore AS
    Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):359-63. PubMed ID: 16492929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect.
    Guindalini RS; Song A; Fackenthal JD; Olopade OI; Huo D
    Cancer; 2016 Jun; 122(12):1913-20. PubMed ID: 26992017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
    Singer CF; Tan YY; Muhr D; Rappaport C; Gschwantler-Kaulich D; Grimm C; Polterauer S; Pfeiler G; Berger A; Tea MM
    Cancer Med; 2019 Apr; 8(4):1875-1881. PubMed ID: 30821131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
    McGee J; Giannakeas V; Karlan B; Lubinski J; Gronwald J; Rosen B; McLaughlin J; Risch H; Sun P; Foulkes WD; Neuhausen SL; Kotsopoulos J; Narod SA;
    Gynecol Oncol; 2017 May; 145(2):346-351. PubMed ID: 28314588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing.
    Lorenzo Bermejo J; Hemminki K
    Ann Oncol; 2004 Dec; 15(12):1834-41. PubMed ID: 15550590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
    Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
    J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ductal carcinoma in situ in BRCA mutation carriers.
    Hwang ES; McLennan JL; Moore DH; Crawford BB; Esserman LJ; Ziegler JL
    J Clin Oncol; 2007 Feb; 25(6):642-7. PubMed ID: 17210933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
    Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND
    Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.
    Borg A; Dørum A; Heimdal K; Maehle L; Hovig E; Møller P
    Dis Markers; 1999 Oct; 15(1-3):79-84. PubMed ID: 10595257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.
    Einbeigi Z; Bergman A; Meis-Kindblom JM; Flodin A; Bjursell C; Martinsson T; Kindblom LG; Wahlström J; Wallgren A; Nordling M; Karlsson P
    Fam Cancer; 2007; 6(1):35-41. PubMed ID: 16944270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Earlier Age of Breast Cancer Onset in Israeli BRCA Carriers-Is it a Real Phenomenon?
    Agranat S; Baris H; Kedar I; Shochat M; Rizel S; Perry S; Margel D; Sulkes A; Yerushalmi R
    Breast J; 2016 Nov; 22(6):662-666. PubMed ID: 27533489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers.
    Streff H; Profato J; Ye Y; Nebgen D; Peterson SK; Singletary C; Arun BK; Litton JK
    Oncologist; 2016 Jul; 21(7):869-74. PubMed ID: 27306910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
    Doren A; Vecchiola A; Aguirre B; Villaseca P
    Climacteric; 2018 Dec; 21(6):529-535. PubMed ID: 30295091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
    Moran O; Nikitina D; Royer R; Poll A; Metcalfe K; Narod SA; Akbari MR; Kotsopoulos J
    Breast Cancer Res Treat; 2017 Jan; 161(1):135-142. PubMed ID: 27798748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk management options elected by women after testing positive for a BRCA mutation.
    Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
    Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.